New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 5, 2014
11:17 EDTGDP, CONN, CIEN, KKD, BIG, DLLR, OVTI, GES, INCY, QCOROptions with decreasing implied volatility
Options with decreasing implied volatility: DLLR CONN INCY BIG GDP GES KKD QCOR OVTI CIEN
News For DLLR;CONN;INCY;BIG;GDP;GES;KKD;QCOR;OVTI;CIEN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 19, 2015
10:02 EDTGESGuess extends its post-earnings rally, levels to watch
The shares were strong performers in the after hours session yesterday following stronger than expected earnings. That rally is extending today with the shares up over 14% yto $19.11. At that price, next resistance is at $19.79. Support is at the 50-day moving average at $18.74. The 50-day has been a proxy for a hand-drawn downtrend resistance line since early 2014. A continued rise above it would turn the longer-term trend bullish.
09:20 EDTGESOn The Fly: Pre-market Movers
Subscribe for More Information
07:15 EDTGESGuess should be sold on post-earnings rally, says Piper Jaffray
Subscribe for More Information
06:00 EDTGESGuess implied volatility of 55 at upper end of index
Subscribe for More Information
March 18, 2015
18:32 EDTGESOn The Fly: After Hours Movers
UP AFTER EARNINGS: Guess (GES), up 12.4% after reporting fourth quarter results and guidance... Shoe Carnival (SCVL), up 10%... NQ Mobile (NQ), up 9.1%... Tilly's (TLYS), up 1.3%... Cintas (CTAS), up 1.3% after reporting quarterly results and raising fiscal 2015 guidance. DOWN AFTER EARNINGS: Williams-Sonoma (WSM), down 4.1%... Jabil Circuit (JBL), down 1.8%... Juno Therapeutics (JUNO), down 3.3%. ALSO LOWER: Concert Pharmaceuticals (CNCE), down 4.4% after filing to sell common stock... Tekmira Pharmaceuticals (TKMR), down 3.7% after filing to sell 6M shares of common stock.
16:53 EDTGESGuess sees currency headwind in 2016
Paul Marciano, CEO, commented, "Turning to the outlook for fiscal year 2016, currencies will definitely be a headwind if they stay at current levels. But, as always, we will remain focused on what we can control, like our North America real estate realignment, providing a unique customer experience within our stores, and tightly managing our costs and inventory levels. We will continue investing in our omni-channel strategy globally and expect it to be a growth vehicle for fiscal 2016. We will also continue to leverage the Marciano brand in our North America Guess stores, and I am very confident in our upcoming product lines for fiscal 2016. Of course, all of these efforts are done with two key priorities in mind: improve the profitability of the Company while at the same time protecting our key asset, the Guess Brand."
16:51 EDTGESGuess says Q4 U.S retail SSS decreased 5%
Subscribe for More Information
16:20 EDTGESGuess sees FY16 revenue growth negative 1% to an increase of 1%
Subscribe for More Information
16:19 EDTGESGuess spikes higher after stronger earnings, first look
Subscribe for More Information
16:18 EDTGESGuess sees Q1 revenue growth of 1%-2%, consensus $491.23M
Subscribe for More Information
16:17 EDTGESGuess sees FY16 EPS 75c-90c, consensus $1.04
16:15 EDTGESGuess sees Q1 EPS (3c)-(6c), consensus (3c)
Subscribe for More Information
16:14 EDTGESGuess reports Q4 EPS 63c, consensus 57c
Reports Q4 revenue $696.7M, consensus $704.59M.
15:20 EDTGESNotable companies reporting after market close
Subscribe for More Information
14:34 EDTGESGuess March volatility elevated into Q4 and outlook
Guess March call option implied volatility is at 167, April is at 55, June is at 43, September is at 38; compared to its 26-week average of 36 according to Track Data, suggesting large near term price movement into the expected release of Q4 results today after the market close.
09:36 EDTGDPActive equity options trading on open
Subscribe for More Information
March 17, 2015
14:42 EDTGESGuess March volatility elevated into Q4 and outlook
Subscribe for More Information
05:32 EDTINCYIncyte announces Novartis receives EC approval for Jakavi
Incyte (INCY) announced that Novartis (NVS) received approval from the European Commission for Jakavi for the treatment of adult patients with polycythemia vera, or PV, who are resistant to or intolerant of hydroxyurea. Jakavi is the first targeted treatment approved by the European Commission for these patients. Under the Incyte-Novartis Collaboration and License Agreement signed in 2009, Novartis received exclusive development and commercialization rights to ruxolitinib outside of the United States for all hematologic and oncologic indications, and sells ruxolitinib under the name Jakavi. Ruxolitinib is marketed by Incyte in the United States as Jakafi. Jakafi is approved by the FDA for treatment of people with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea. Jakafi is also indicated for treatment of people with intermediate or high-risk myelofibrosis, or MF, including primary MF, post–polycythemia vera MF, and post–essential thrombocythemia MF.
March 13, 2015
11:19 EDTINCYBioMarin rallies amid positive call on DMD drug timeline, takeover rumor
The shares of drug maker BioMarin (BMRN) are climbing after research firm Jefferies quoted a regulatory expert as saying that the company's drisapersen drug has a good chance of being approved on an accelerated basis by the FDA. Drisapersen is a treatment for Duchenne Muscular Dystrophy, or DMD. WHAT'S NEW: "There is a strong possibility" that the FDA will grant accelerated approval to drisapersen because there is currently no approved drug for the treatment of DMD, Jefferies analyst Eun Yang quoted the expert as saying. The expert is also optimistic about the outlook for accelerated approval because she had a good experience working with BioMarin while she was with the FDA and because BioMarin has a favorable track record with the FDA, according to Yang. There is a 60% chance that drisapersen will be approved by the end of this year and the stock can rise to $155, versus its current level of about $121.50, if that does occur, the analyst stated. Yang's price target on the stock increased to $135 from $125 and the analyst kept a Buy rating on the shares. WHAT'S NOTABLE: Pharmaceutical giant AstraZeneca (AZN) has been rumored to be interested in buying BioMarin for $175 per share in cash, British newspaper Daily Mail reported. , Piper Jaffray analyst Joshua Schimmer wrote in a note to investors this morning that BioMarin, along with Vertex (VRTX) and Incyte (INCY), have a "clear path" to joining the group of companies with market caps of over $10B projected to deliver greater than 20% EPS CAGR, which the analyst identified as a set of criteria that has previously pointed to companies that make good potential takeover targets. PRICE ACTION: In mid-morning trading, BioMarin climbed nearly 4% to $120.
07:36 EDTGESGuess March volatility elevated into Q4 and outlook
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use